Using Modalert to Reduce Chronic Daytime Sleepiness can reduce the effects of chronic daytime sleepiness conditions. Participants in the study had to have chronic excessive sleepiness on work nights or during commutes home, as well as a sleep efficiency of 87.5 percent or less on daytime polysomnography.The study was performe after written informe consent was obtained.
An indirect treatment comparison meta-analysis compared two different sleep-reduction medications for the treatment of chronic daytime sleepiness in patients with obstructive sleep apnea. The primary outcomes were improvement in the patients’ self-reporte fatigue (single item scale or questionnaire instruments), mean improvement in the patients’ SSS, and compliance with the therapy. Secondary outcomes included depression and adverse effects.
Narcolepsy, a condition that causes excessive daytime sleepiness, and shift work sleep disorder are both conditions that are treated with modafinil (sleepiness during scheduled waking hours and difficulty falling asleep or staying asleep during scheduled sleeping hours in people who work at night or on rotating shifts)
Patients with chronic daytime sleepiness were includ in this study if they were able to receive a complete evaluation of their symptoms, including the presence of OSA, SWD, or narcolepsy. This evaluation included a detailed history, physical exam, and possibly laboratory tests. Patients with more than one sleep disorder may be exclud from the trial because of the potential side effects of the drug.
Modafinil is a wake-promoting drug used to treat chronic daytime sleepiness in people with narcolepsy, shift work disorder. And obstructive sleep apnea. Its mechanism of action is similar to that of classical psychostimulants and involves the histaminergic system. It activates both direct and indirect histaminergic neurons by attenuating inhibitory GABAergic input.
Primary efficacy variables are predefined.
Prespecified primary efficacy variables for the Modalert study were ESS (Epworth Sleepiness Scale), LS (least squares), MWT (Maintenance of Wakefulness Test), and PGI-C (Patient Global Impression of Change). The study was designe to measure the effects of Modalert or Modalert 200 on sleepiness and wakefulness.
Eligible patients had to be literate in English and provide informed consent. In addition, their insomnia diagnosis had to be based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. They also had to have an ISI (Sleepiness Index) of 15 or greater. Moreover, patients were exclud if they had any history of CBT, had been hypnotic-free for four weeks, or were pregnant.
The study also includes trials with a placebo. The first trial with a significant difference compare with placebo is then followed by trials with a non-significant difference. The last trial with significant results is the fifth and final trial. Which also includes co-primary efficacy endpoints, the Maintenance of Wakefulness Test sleep latency, and Epworth Sleepiness Scale scores.
The root of the sleep disturbance must be addressed before hypersomnia, or excessive daytime sleepiness, may be treated. For instance, if sleep apnea is determined to be the cause of your condition, your doctor may advise you to utilise continuous positive airway pressure (CPAP) therapy while you sleep. In order to use CPAP, you must wear a mask over your nose that is connected to a device that continuously squirts air into your nostrils. The airways are kept open by the pressure of air entering the nose.